- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02037724
Fermented Iron-rich Supplement in Reducing Anemia (FISRA)
The consequences of iron deficiency anemia in women are enormous, and especially in developing countries, as the condition adversely affects both their productive and reproductive capabilities. The study seeks to: 1) compare changes in iron status indicators among women receiving an iron-rich organic food supplement versus ferrous sulfate supplement, and 2) determine the suitable level of food supplement needed to prevent/reduce iron deficiency anemia among women in developing country settings.
A double-blind, randomized, controlled, intervention trial will be implemented in women of childbearing age, 60 women with iron deficiency anemia and 60 women with iron deficiency. After screening potential subjects (up to 500 expected), approximately 30 will be recruited into each of four study groups; assuming 30% dropout rate, to detect an increase of 30% in ferritin as significant between the two time points at 80% power and alpha value of 0.05. Subjects who meet the inclusion criteria will be randomized into the four groups consisting of: 2 control groups (daily 60mg ferrous sulfate (FS-60) or daily 10mg ferrous sulfate (FS-10)), and 2 test groups (daily 60mg iron-rich supplement (IRS-60) or 10mg iron-rich supplement (IRS-10)). Subjects will take daily FS-60 and IRS-60 under supervision for 8 weeks while subjects taking FS-10 and IRS-10 will take the supplement under supervision for 12 consecutive weeks.
Study Overview
Status
Conditions
Detailed Description
The design will involve screening of about 500 female adult students and staff of the University of Ghana who meet initial the inclusion criteria. Screening will involve pregnancy testing, assessment of hemoglobin, and ferritin and also administration of a health history questionnaire.
Thereafter, 120 eligible subjects will enrolled and randomized to recieve the treatment. All subjects will complete 3-day dietary record (including 2 weekdays and 1 weekend) at baseline and at endline (i.e. one week prior to treatment completion). The dietary data will be analyzed using nationally-generated food composition tables together with the ESHA food processor software. In addition, body weight and height will be measured using standard methods at baseline and end of the study. Weekly monitoring of side effects will be recorded. Fasting blood samples will be collected at baseline and endline to enable determination of anemia status and other indicators including serum ferritin, transferrin receptor and full blood count, together with C-reactive protein.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Richmond Aryeetey, PhD
- Phone Number: 233244129669
- Email: raryeetey@ug.edu.gh
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-49 years
- Regular menstruation in the last three months
- Hemoglobin <12 mg/dl;
- Serum Ferittin<20mcg/L
- BMI 18.5Kg/m^2 to 29.9 kg/m^2
Exclusion Criteria:
- history of gastrointestinal or hematological disorders,
- taking medications that could interfere with hematopoiesis or dietary iron absorption
- pregnant (based on pregnancy test).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: supplement containing 60 mg iron sulfate
nutrient supplement containing 60 mg of iron as ferous sulfate
|
contains 60 mg of iron
contains 10 mg iron
control agent
|
Experimental: iron rich food supplement (60 mg iron)
contains 60 mg Iron
|
contains 10 mg iron
control agent
control agent
|
Experimental: iron rich food supplement (10 mg iron)
contains 10 mg of iron
|
contains 60 mg of iron
control agent
control agent
|
Other: supplement containing 10 mg iron sulfate
nutrient supplement containing 10 mg of iron as ferous sulfate
|
contains 60 mg of iron
contains 10 mg iron
control agent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
iron deficiency anemia
Time Frame: two and three months
|
Improvement of iron status with 60 mg (after two months) and 10 mg iron (after 3 months) will be assessed.
The iron status measurements include, hemoglobin, ferritin, transferrin receptor and whole blood count
|
two and three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
comparison of side effects of iron supplement
Time Frame: 3 months
|
We expect to have less side effects with IRS compared with ferrous sulfate (as observed in previous studies) that include: constipation, diarrhea, vomiting, gastrointestinal distress, change in stool color and others.
We will assess these with a questionnaire.
|
3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
minimum level of supplement intake needed to improve iron status
Time Frame: 3 months
|
The effectiveness of low dose (10 mg daily iron) compared to higher dose (60mg daily iron) from the fermented organic food supplement product.
These results will be helpful for using IRS as a food supplement.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richmond Aryeetey, PhD, University of Ghana
- Principal Investigator: Manju Reddy, PhD, Iowa State University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UG-0001-IDA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Deficiency Anemia
-
Pennington Biomedical Research CenterRecruitingIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia TreatmentUnited States
-
Children's Hospital Los AngelesNot yet recruitingAnemia | Iron Deficiency Anemia | Anemia, Iron Deficiency | IDA - Iron Deficiency AnemiaUnited States
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
Arrowhead Regional Medical CenterRecruitingIron Deficiency Anemia of PregnancyUnited States
-
Luzerner KantonsspitalRecruitingIron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron DeficienciesSwitzerland
-
Swiss Federal Institute of TechnologyUnited States Agency for International Development (USAID); Quadram Institute... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)Peru
-
Children's Hospital Los AngelesWithdrawnAnemia | Iron-deficiency Anemia | Healthy ControlsUnited States
-
Baylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI)CompletedIron-deficiency | Iron Deficiency AnemiaUnited States
-
Iowa State UniversityCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron Deficiency Anaemia Due to Dietary CausesUnited States
-
Société des Produits Nestlé (SPN)CompletedIron-deficiency | Anemia | Iron Deficiency AnemiaPhilippines
Clinical Trials on iron rich food supplement (60 mg iron)
-
George Washington UniversityColumbia University; Harvard School of Public Health (HSPH); Ifakara Health Institute and other collaboratorsNot yet recruiting
-
McGill UniversityWorld Vision; Foreign Affairs, Trade and Development, CanadaCompleted
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...UnknownCeliac Disease | Iron Deficiency (Without Anemia)Italy
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
HaEmek Medical Center, IsraelCompleted
-
George Washington UniversityColumbia University; Harvard School of Public Health (HSPH); Ifakara Health Institute and other collaboratorsNot yet recruiting
-
George Washington UniversityColumbia University; Harvard School of Public Health (HSPH); Ifakara Health Institute and other collaboratorsNot yet recruiting
-
IBSA Farmaceutici Italia SrlInformapro SrlRecruiting
-
Haukeland University HospitalUnknown
-
The Hospital for Sick ChildrenCompleted